Penile-preserving surgery for primary urothelial carcinoma of male urethra  by Tai, Haoping et al.
lable at ScienceDirect
Urological Science 26 (2015) 131e133Contents lists avaiUrological Science
journal homepage: www.urol-sci .comCase reportPenile-preserving surgery for primary urothelial carcinoma of male
urethra
Haoping Tai a, *, Jue-Hawn Yin a, Zhon-Min Huang a, Tang-Yi Tsao b
a Division of Urology, Department of Surgery, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan
b Department of Pathology, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwana r t i c l e i n f o
Article history:
Received 7 April 2014
Received in revised form
26 February 2015
Accepted 2 March 2015




urothelial carcinoma* Corresponding author. Division of Urology, Dep
699, Section 8, Taiwan Boulevard, Wuqi District, Taich
E-mail address: taihaoping@gmail.com (H. Tai).
http://dx.doi.org/10.1016/j.urols.2015.03.001
1879-5226/Copyright © 2015, Taiwan Urological Assoa b s t r a c t
Primary urethral carcinoma is a rare cancer, comprising <1% of all malignancies. The location of this
lesion presents a certain dilemma of treatment between efﬁcacy and quality of life. We report an 84-
year-old male patient, with a history of chronic hepatitis C, hypertension, and transient ischemic acci-
dent, who presented with dysuria and acute urinary retention. The intravenous urography showed mild
prostatic enlargement, but no stone or ﬁlling defect was noted in the upper urinary tract. On ure-
throcystoscopy, multiple papillary tumors were found at the pendulous urethra, and the pathology of
biopsy conﬁrmed urothelial carcinoma. The patient was admitted, and electroresection with fulguration
of urethral tumors was performed owing to the patient's old age and poor performance status. Intra-
urethral and intravesical chemotherapy with mitomycin C was regularly given at the outpatient clinic.
Recurrent urothelial carcinomas were noted twice in the ﬁrst 2 years of follow up, and repeated tran-
surethral resections were done. Unfortunately, liver cirrhosis with hepatocellular carcinoma was diag-
nosed last June, for which he received transcatheter arterial chemoembolization. No recurrence of
urethral cancer has been found on semiannual cystoscopy in the past 3 years. Penile-preserving surgery
is a reasonable surgical option for elderly primary urethral carcinoma patients with acceptable onco-
logical outcome and good quality of life.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Primary urethral carcinoma (PUC) is a rare malignancy,
comprising <1% of all malignancies, and having an incidence rate of
4.3/million inmales and 1.5/million in females.1 Risk factors include
urethral stricture, chronic inﬂammation or irritation of urethra, and
irradiation therapy. Histologic types are mainly transitional cell
carcinoma (55%), squamous cell carcinoma (21.5%), and adenocar-
cinoma (16.4%).1 The overall survival and disease-speciﬁc survival
rates at 5 years were 42% and 50%, respectively.2
The treatment of localized PUC in males has followed the pro-
cedure for penile cancer with aggressive surgical excision in the
past. According to the European Association of Urology 2013
guidelines on PUC, penile-preserving surgery could now be
deemed as an alternative to primary urethectomy.3 Age, grade,artment of Surgery, Number
ung City 435, Taiwan.
ciation. Published by Elsevier TaiwTNM stage, histology, and extent of surgery were prognostic factors
predictive of overall and cancer-speciﬁc survival.4
We report a case of primary urothelial carcinoma of distal
urethra in an 84-year-old man, who was treated with electro-
resectionwith fulguration and followed up at our urology clinic for
4.5 years.2. Case Report
An 84-year-old man visited our urology clinic with a chief
complaint of voiding difﬁculty for 2 weeks in December 2009. He
had a history of chronic hepatitis C, hypertension, transient
ischemic accident, and cigarette smoking for >30 years. At the
clinic, digital rectal examination revealed a walnut-sized prostate
with a rubbery consistency and smooth surface. No palpable or
visible lesionwas observed in the external genitalia or inguinal area
on physical examination. The intravenous urography showed mild
basal indentation of the urinary bladder due to benign prostatic
hyperplasia. No ﬁlling defect was noted in the urinary bladder or
the upper urinary tract (Fig. 1A).an LLC. Open access under CC BY-NC-ND license.
Fig. 1. (A) Intravenous urography shows mild basal indentation of the bladder owing to benign prostatic hyperplasia (BPH); patent bilateral ureters and no ﬁlling defect in kidney
and urinary bladder. (B) Urethrocystoscopy reveals multiple papillary tumors of the pendulous urethra.
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normal except for an elevated liver function test result (aspartate
aminotransferase 74 IU/L, and alanine transaminase 64 IU/L). The
prostate-speciﬁc antigen level was 4.1 ng/dL, which was normal for
his age. Urinalysis revealed mild pyuria (5e10 white blood cells/
high power ﬁeld). Urethrocystoscopy was arranged, and multiple
papillary tumors at the pendulous urethrawere found 7e8 cm from
the urethral meatus (Fig. 1B). Cystoscopiccold-cup biopsies were
done, and the pathology report conﬁrmed grade 1 urothelial car-
cinoma of the urethra at T1 stage (limited at lamina propria; Fig. 2).
An abdominal computed tomography was performed, which
showed no lymphadenopathy or distant organ metastasis.
The patient was admitted for surgical intervention, and elec-
troresection of the urethral tumor with fulguration was performed
because of his (old) age. He was discharged home with medication
for benign prostatic hyperplasia. Intraurethral and intravesical
chemotherapy with mitomycin C (30 mg) was administered at our
urology clinic weekly for 4 weeks and then monthly. Mitomycin C
dissolved in 30 mL of normal saline was instilled along the way
from the urinary bladder to the distal urethra by slowly pulling out
the urethral catheter. A penile clamp was applied to the distal
urethra for 30 minutes after instillation. Two recurrences of PUC
were noted on follow-up urethrocystoscopy in March 2010 and July
2012, respectively. Repeated transurethral resections of urethral
tumors with fulguration were performed. Urethral stricture withFig. 2. (A) Histologic examination of the cystoscopic biopsy of the urethral tumor show
stalks, and increased cell layers (hematoxylineeosin stain, 20). (B) The tumor cells sh
(hematoxylineeosin stain, 400).urinary retention occurred once in October 2013 and was relieved
by optic urethrotomy.
The patient also had chronic hepatitis C-related liver cirrhosis,
Child-Pugh B, with ascites and hepatocellular carcinoma, T2N0M0.
Transcatheter arterial chemoembolization was performed for the
hepatocellular carcinoma in June 2013. No recurrence of urothelial
carcinoma of the urethra has been noted at follow up in the past 2
years.
3. Discussion
PUC is an uncommon cancer and can metastasize to tissues
around the urethra and inguinal or pelvic lymph nodes. The rarity
and location of PUC render its treatment option a difﬁcult choice
between efﬁcacy of tumor control and quality of life. Therefore,
there is a lack of consensus on the optimal treatment for PUC. There
is an agreement that clinical management should be primarily
based on the clinical stage and location of the tumors. The overall
survival rate was 83% for superﬁcial disease versus 36% for more
advanced cancers.2 Clinical staging provides the strongest prog-
nostic indication of survival.5 Early detection affords the best
outcome of treatment.
Symptoms and signs of PUC include hematuria, urethral
bleeding, urethral discharge, dysuria, frequent urination, a lump in
the penis, and enlarged lymph nodes in the inguinal area. Thes low-grade urothelial carcinoma with papillary growth pattern, branching vascular
ow relatively uniform nuclei with some prominent nucleoli and common mitosis
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anterior urethral cancer.2 It is pivotal to ﬁnd and locate the urethral
tumor at early stages with cystoscopy. Intravenous urography and
computed tomography scans are also important tools for checkup
of the upper urinary tract and pelvic and abdominal lymph node
metastases. Magnetic resonance imaging can provide more local
anatomic detail and excellent soft-tissue contrast that can increase
the accuracy of staging, so it may serve as a better alternative for
image checkup.
Most of the information of treatment of PUC is derived from
retrospective and singe-center case series. The choice of treatment
is hence not standardized owing to the rarity of PUC. Surgery re-
mains the cornerstone of therapy, and the approach depends on
tumor grade, stage, and location. Previously, radical surgery to
achieve a wide safety margin was recommended. The European
Association of Urology has issued guidelines on PUC in 2013 and
recommended penile-preserving surgery as an alternative to pri-
mary urethrectomy, if negative surgical margins can be achieved.3
Ablative surgical techniques, such as electroresection with fulgu-
ration, or laser vaporization with coagulation, can be used to pre-
serve the penis and urethra in aged patients with superﬁcial distal
urethral cancer.6
Invasive primary carcinoma of the male urethra has a dismal
outcome even with extensive surgical extirpation or radiation
therapy. Coordinated chemoradiation therapy has been postulated
for the primary treatment of invasive PUC with good response. The
5-year overall and disease-speciﬁc survival rates were 60% and
83%, respectively.7 Multimodal treatment with surgery and che-
moradiation is the optimal treatment for advanced urethral
carcinoma.
In our case, this 84-year-old patient had received three tran-
surethral resections, and no recurrence has been noted in the past 2years. It is consistent with the recommendation in the literature
that superﬁcial distal urethral cancer could be treated with endo-
scopic transurethral resection with preservation of organ function.
In conclusion, PUC has a more favorable prognosis in early stage
and anterior urethra. Superﬁcial anterior urethral carcinoma can be
managed endoscopically using electroresection or laser vapor-
ization, especially in aged patients, who are not legitimate candi-
dates for radical surgery.
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